Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells
Authors:
Open Access
- 15 December 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (5) , 6270-6281
Abstract
Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cellsKeywords
This publication has 64 references indexed in Scilit:
- Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationProceedings of the National Academy of Sciences, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Cross‐species chemogenomic profiling reveals evolutionarily conserved drug mode of actionMolecular Systems Biology, 2010
- The p53 orchestra: Mdm2 and Mdmx set the toneTrends in Cell Biology, 2010
- Identification and Characterization of the First Small Molecule Inhibitor of MDMXJournal of Biological Chemistry, 2010
- Ribosomal Protein S7 Is Both a Regulator and a Substrate of MDM2Molecular Cell, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?Molecular Cancer Research, 2009
- Mechanisms mediating androgen receptor reactivation after castrationUrologic Oncology: Seminars and Original Investigations, 2009
- The Mdm2 RING domain C‐terminus is required for supramolecular assembly and ubiquitin ligase activityThe EMBO Journal, 2006